• 1. Gastrodin extends the lifespan and protects against neurodegeneration in the Drosophila PINK1 model of Parkinson's disease
  Jianzheng He,Xu Li,Shipei Yang,Yaling Li,Xingyao Lin,Minghui Xiu,Xuexiang Li,Yongqi Liu Food Funct. 2021 12 7816
• 2. Effects and mechanism of gastrodin supplementation on exercise-induced fatigue in mice
  Mingjun Zhang,Shumao Cui,Bingyong Mao,Qiuxiang Zhang,Jianxin Zhao,Xin Tang,Wei Chen Food Funct. 2023 14 787
• 3. Efficient acylation of gastrodin by Aspergillus oryzae whole-cells in non-aqueous media
  Xiaofeng Li,Maohua Ma,Xuan Xin,Yuqian Tang,Guanglei Zhao,Xinglong Xiao RSC Adv. 2019 9 16701
• 4. A study on the catalytic activity of polypeptides toward the hydrolysis of glucoside compounds gastrodin, polydatin and esculin
  Juan Hou,Xiangmin Lei,Borui Liu,Zejiang Wang,Guozhen Fang,Jifeng Liu,Shuo Wang J. Mater. Chem. B 2022 10 9878
• 5. Effects of gastrodin against carbon tetrachloride induced kidney inflammation and fibrosis in mice associated with the AMPK/Nrf2/HMGB1 pathway
  Jie-Qiong Ma,Yun-Zhi Sun,Qing-Lei Ming,Zhi-Kai Tian,Yu-Jia Zhang,Chan-Min Liu Food Funct. 2020 11 4615

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Phenolic glycosides
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether

Gastrodin (CAS No. 62499-27-8): A Comprehensive Overview of Its Applications and Recent Research Findings

Gastrodin, chemically known by the CAS number 62499-27-8, is a naturally occurring compound that has garnered significant attention in the field of pharmaceuticals and biomedical research. This compound, derived from the rhizome of Rehmannia glutinosa, has been traditionally used in Eastern medicine for its potential therapeutic properties. With advancements in chemical and biological sciences, Gastrodin has emerged as a subject of extensive research, particularly for its neuroprotective, anti-inflammatory, and antioxidant effects.

The molecular structure of Gastrodin consists of a glucose moiety linked to a γ-glutamyl moiety, which contributes to its unique pharmacological profile. This structural feature allows Gastrodin to interact with various biological targets, making it a versatile candidate for multiple therapeutic applications. The compound's stability and bioavailability have been subjects of interest in drug formulation studies, ensuring its efficacy in clinical settings.

Recent studies have highlighted the neuroprotective properties of Gastrodin, particularly in the context of neurodegenerative diseases such as Alzheimer's and Parkinson's. Research indicates that Gastrodin can mitigate oxidative stress and inflammation in neural cells, thereby protecting against neuronal damage. For instance, a study published in the Journal of Neural Transmission demonstrated that Gastrodin treatment could significantly reduce beta-amyloid accumulation and improve cognitive function in animal models of Alzheimer's disease.

In addition to its neuroprotective effects, Gastrodin has shown promise in treating various inflammatory conditions. Its anti-inflammatory properties are attributed to its ability to inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6. A study published in the European Journal of Pharmacology reported that Gastrodin could effectively reduce inflammation in rheumatoid arthritis models by modulating immune responses.

The antioxidant potential of Gastrodin has also been extensively studied. Reactive oxygen species (ROS) are known to contribute to cellular damage and aging, and Gastrodin has been shown to scavenge ROS, thereby protecting cells from oxidative stress. Research published in the Free Radical Biology and Medicine journal highlighted that Gastrodin could enhance the activity of endogenous antioxidant enzymes like superoxide dismutase (SOD) and catalase.

Moreover, Gastrodin's role in enhancing synaptic plasticity has been explored in recent years. Synaptic plasticity is crucial for learning and memory, and impairments in this process are associated with cognitive decline. Studies have shown that Gastrodin can promote long-term potentiation (LTP), a phenomenon associated with enhanced synaptic transmission. This finding makes Gastrodin a potential therapeutic agent for cognitive disorders.

The pharmacokinetic profile of Gastrodin has also been a focus of research. Studies have investigated its absorption, distribution, metabolism, and excretion (ADME) properties to optimize its delivery systems. Nanotechnology-based drug delivery systems have been explored to enhance the bioavailability of Gastrodin. For example, lipid nanoparticles have been shown to improve the systemic circulation time of Gastrodin, thereby increasing its therapeutic efficacy.

Clinical trials have begun to evaluate the safety and efficacy of Gastrodin in human populations. Preliminary results suggest that Gastrodin is well-tolerated with minimal side effects. These trials are particularly focused on conditions such as epilepsy, stroke recovery, and age-related cognitive decline. The ongoing clinical studies aim to provide further evidence supporting the use of Gastrodin as a therapeutic agent.

The future direction of Gastrodin research includes exploring its potential role in combination therapies. By synergizing Gastrodin with other pharmacological agents, researchers aim to develop more effective treatment strategies for complex diseases. Additionally, computational modeling and high-throughput screening techniques are being employed to identify new derivatives of Gatrodon with enhanced pharmacological properties.

In conclusion, Gatrodon (CAS No. 62499-27-8) is a promising natural compound with diverse therapeutic applications. Its neuroprotective, anti-inflammatory, and antioxidant properties make it a valuable candidate for treating various diseases, particularly neurodegenerative disorders. Ongoing research continues to unravel the mechanisms underlying its pharmacological effects and explore novel delivery systems to enhance its clinical utility.

• 358681-61-5(4-Methoxyphenyl 2,3,6-tri-O-benzyl-4-O-(2,6-di-O-benzyl-b-D-galactopyranosyl)-b-D-glucopyranoside)
• 303127-80-2(4-Methoxyphenyl 3-O-Benzyl-β-D-glucopyranoside)
• 383905-60-0(4-Methoxyphenyl 3-O-Benzyl-b-D-galactopyranoside)
• 106982-96-1(b-D-Allopyranoside,4-(hydroxymethyl)phenyl)
• 159922-50-6(4-Methoxyphenyl 2,6-Di-O-bezyl-β-D-galactopyranoside)
• 176299-96-0(b-D-Galactopyranoside,4-methoxyphenyl 4,6-O-[(S)-phenylmethylene]-)
• 143536-99-6(4-Methoxyphenyl 2,3,4,6-Tetra-O-benzyl-β-D-galactopyranoside)
• 247027-79-8(4-Methoxyphenyl 2,4,6-Tri-O-benzyl-β-D-galactopyranoside)
• 717132-49-5(4-Methoxyphenyl 4-O-(2,4,6-tri-O-benzyl-b-D-galactopyranosyl)-2,3,6-tri-O-benzyl-b-D-glucopyranoside)
• 150412-81-0(4-Methoxyphenyl 4-O-(2,3,6-tri-O-benzyl-b-D-galactopyranosyl)-2,3,6-tri-O-benzyl-b-D-glucopyranoside)